With an Extended Fertility Technologies Portfolio Merck now Covers all IVF Steps

"As the worldwide leader in fertility treatments, Merck continues to focus on innovation, in order to enable clinics to make individualized treatment decisions with and for their patients," said Rehan Verjee, Chief Marketing and Strategy Officer at the biopharma business of Merck. "Both Gidget and Geri+ increase embryologists’ options to provide the best possible treatment solutions for women and couples wanting to have a baby, such as offering greater safety and assurance for IVF patients and enabling a personalized workflow management and patient tracking."

GidgetTM and GeriTM+ stem from the ARTinnovations development hub, which Merck formed in collaboration with Genea Biomedx Propriety Ltd., Sydney, Australia. ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. It combines the commitment and know-how of both partners to develop ideas that can take root and grow into better outcomes for patients.

Integrating bright- and dark-field imaging, the GeriTM+ incubator now allows for combination with the Eeva® software and any Geri Assess version. Geri+ becomes a multifunctional incubator, which gives embryologists a multitude of possibilities around embryo analytics. It brings together the benefits of undisturbed incubation, while complying with the high control and safety standards of the GeriTM incubator and the analytics of the Eeva® software, the first automated algorithm clinically shown to improve embryo assessment.1,2,3

GidgetTM is a hand-held device for the IVF laboratory that lets the embryologist focus on the science by eliminating any chance of mismatching, and includes unique tracking and workflow features. It provides electronic witnessing, lab workflow management and support for traceability and audit reporting.

Both products will be available immediately in Europe and Canada, with GidgetTM also launching in the US, Japan and additional regions set to follow soon.

References

1.VerMilyea MD, et al. Repromed Biomed Online. 2014; 29(6):729-736

2.Diamond MP, et al.J Assist Reprod Genet. 2015 Jan;32(1):61-8

3.Adamson GD, et al. Fertil Steril 2016; 105(2):369-375

News Release

About GidgetTM and GeriTM+

GidgetTM is designed as easy-to-use hand-held device to aid sample identification and tracking during ART procedures. GidgetTM is used to scan dishes, tubes and other consumables used to maintain and process patient material to eliminate mismatching from occurring. However, GidgetTM provides further functionalities and benefits for the lab than a pure witnessing system, enabling a personalized intelligent ART assistance for clinical workflow management and patient tracking.

GeriTM+ is an innovative multifunctional incubator with individually controlled incubation chambers per patient and a camera to real time monitor the developing embryos, now combinable with the analytics of the Eeva® software. To give each embryo the best chance of development, GeriTM+ is designed to provide undisturbed incubation environment with the highest control and safety standards.

About the ARTinnovations hub

The development hub ARTinnovations is an incubator for ideas and innovations for fertility treatment and technologies. A collaboration between Genea Biomedx and Merck, ARTinnovations provides the support and know-how to develop ideas so that they take root and grow into better outcomes for patients. Building on its strong heritage in fertility treatment, Merck aims to jointly develop an innovative pipeline of fertility technologies and services through the ARTinnovations hub, to help support patients undergoing ART and provide healthcare professionals with objective information to make important treatment decisions.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.